Table 1.
Selected Phase III Clinical Trial Results for Patients Coinfected With HIV and HCV Genotype 1a
| CROI 2015 Abstract (Study) | Regimen | No. | SVR12 Rate | Treatment Naive | Treatment Experienced | No Cirrhosis | Cirrhosis | |
|---|---|---|---|---|---|---|---|---|
| 151LB (ALLY-2) | Sofosbuvir and daclatasvirb for 12 weeks | 127 | 97% | 96% (80/83) | 98% (43/44) | 98%c (98/100) | 91%c (20/22) | |
| 151 LB (ALLY-2) | Sofosbuvir and daclatasvirb for 8 weeks | 41 | 76% | 76% | NA | 78% (28/36) | 60% (3/5) | |
| 152LB (ION-4) | Sofosbuvir and ledipasvir for 12 weeks | 327 | 96% | 95% (138/146) | 97% (175/181) | 96% (250/260) | 94% (63/67) | |
Abbreviations: CROI, Conference on Retroviruses and Opportunistic Infections; HCV, hepatitis C virus; NA, not applicable; SVR12, sustained virologic response 12 weeks after cessation of therapy.
a
See text for additional details. Subgroups calculated from data presented.
b
Investigational drug in the United States.
c
5 participants had indeterminate cirrhosis status at baseline; all achieved SVR12.